Rhythm Pharmaceuticals

Yahoo Finance • 15 days ago

Nvidia, These Other AI Plays Lead 5 Stocks Near Buy Points

Three of the five stocks to watch are part of the artificial intelligence trade, including chip company Nvidia. Continue Reading View Comments... Full story

Yahoo Finance • 21 days ago

2 Under-the-Radar Stocks That Could Soar

Key Points Terns Pharmaceuticals and Rhythm Pharmaceuticals are developing weight loss medicines. Terns Pharmaceuticals has an upcoming data readout for a promising oral candidate. Rhythm Pharmaceuticals is targeting label expansions for... Full story

Yahoo Finance • 2 months ago

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

BOSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today anno... Full story

Yahoo Finance • 2 months ago

Rhythm Pharma label expansion requests for obesity drug undergo U.S. EU reviews

[Open notebook with review. Feedback collection and personal reflection.] designer491/iStock via Getty Images Rhythm Pharmaceuticals (NASDAQ:RYTM [https://seekingalpha.com/symbol/RYTM]) announced that U.S. and EU regulators have accepted... Full story

Yahoo Finance • 2 months ago

FDA Accepts Rhythm Pharma' SNDA For Setmelanotide To Treat Acquired Hypothalamic Obesity

(RTTNews) - Rhythm Pharmaceuticals, Inc. (RYTM) announced that the U.S. Food and Drug Administration has accepted for filing the company's supplemental New Drug Application or sNDA for setmelanotide seeking approval for the treatment of co... Full story

Yahoo Finance • 2 months ago

Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity

– U.S. Food and Drug Administration accepts sNDA for filing with priority review; sets PDUFA goal date of December 20, 2025 -- – European Medicines Agency accepts and validates submission for Type II variation MAA for setmelanotide to tre... Full story

Yahoo Finance • 2 months ago

Rhythm pharmaceuticals corporate controller sells $142,500 in shares

Boston, MA - Christopher Paul German, Corporate Controller & CAO at Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), sold 1,500 shares of common stock on August 12, 2025, according to a Form 4 filing with the Securities and Exchange Commission.... Full story

Yahoo Finance • 2 months ago

Rhythm Pharma CFO Smith sells $2.7m in shares

Rhythm Pharmaceuticals (NASDAQ:RYTM), a $6.4 billion market cap biotech company with impressive gross profit margins of 89%, saw Chief Financial Officer Hunter C. Smith sell 28,088 shares of common stock on August 12 and 13, according to a... Full story

Yahoo Finance • 2 months ago

Shulman Joseph of Rhythm Pharma sells $358,891 in shares

Rhythm Pharmaceuticals (NASDAQ:RYTM), a $6.5 billion market cap biotech company whose stock has surged 112% over the past year, reported that Chief Technical Officer Joseph Shulman sold 3,984 shares of common stock on August 11, 2025, at p... Full story

Yahoo Finance • 2 months ago

Rhythm Pharma earnings missed by $0.08, revenue topped estimates

Investing.com - Rhythm Pharma (NASDAQ: RYTM) reported second quarter EPS of $-0.75, $0.08 worse than the analyst estimate of $-0.67. Revenue for the quarter came in at $48.5M versus the consensus estimate of $43.75M. Rhythm Pharma’s sto... Full story

Yahoo Finance • 2 months ago

Rhythm Pharmaceuticals Q2 2025 slides: Revenue jumps 29%, obesity drugs show promise

Introduction & Market Context Rhythm Pharmaceuticals (NASDAQ:RYTM) presented its second quarter 2025 financial results and business update on August 5, 2025, highlighting strong revenue growth and significant clinical progress for its obe... Full story

Yahoo Finance • 2 months ago

Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) Reports Mixed Q2 2025 Earnings: Revenue Beat Overshadowed by Wider Losses

Rhythm Pharmaceuticals Inc (NASDAQ:RYTM [https://www.chartmill.com/stock/quote/RYTM/profile]) reported its second-quarter 2025 financial results, delivering mixed performance relative to analyst expectations. The company's revenue exceeded... Full story

Yahoo Finance • 2 months ago

Rhythm Pharmaceuticals Q2 2025 Earnings Preview

* Rhythm Pharmaceuticals (NASDAQ:RYTM [https://seekingalpha.com/symbol/RYTM]) is scheduled to announce Q2 earnings results on Tuesday, August 5th, before market open. * The consensus EPS Estimate is -$0.67 [https://seekingalpha.com/sym... Full story

Yahoo Finance • 2 months ago

Rhythm pharmaceuticals exec Cramer sells $130k in shares

Pamela J. Cramer, Chief Human Resources Officer at Rhythm Pharmaceuticals, INC. (NASDAQ:RYTM), sold 1,520 shares of common stock on July 29 at a price of $85.93, totaling approximately $130,613. The transaction comes as the $5.6 billion ma... Full story

Yahoo Finance • 2 months ago

Cramer, Rhythm Pharmaceuticals' CHRO, sells $130k in shares

Pamela J. Cramer, Chief Human Resources Officer of Rhythm Pharmaceuticals (NASDAQ:RYTM), sold 1,520 shares of common stock on July 29, 2025, at a price of $85.93, for a total value of $130,613. The transaction comes as the $5.6 billion mar... Full story

Yahoo Finance • 3 months ago

Rhythm Pharmaceuticals to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025

BOSTON, July 22, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today anno... Full story

Yahoo Finance • 3 months ago

Canaccord Genuity raises Rhythm Pharmaceuticals stock price target on obesity treatment potential

Investing.com - Canaccord Genuity raised its price target on Rhythm Pharmaceuticals (NASDAQ:RYTM) to $105.00 from $92.00 on Friday, while maintaining a Buy rating on the stock. The company, now valued at nearly $6 billion, has seen its sha... Full story

Yahoo Finance • 3 months ago

Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025

- Presentations highlight clinically meaningful reductions in BMI in patients with acquired hypothalamic obesity – - Full data from Phase 3 TRANSCEND study underscore potential efficacy of setmelanotide, including with prior use or concom... Full story

Yahoo Finance • 3 months ago

Investing.com’s stocks of the week

Investing.com -- Markets concluded the week with a notable shift in sentiment. After reaching record highs earlier, U.S. stocks closed lower on Friday, impacted by macroeconomic concerns. Here are Investing.com’s stocks of the week. Core... Full story

Yahoo Finance • 3 months ago

Oppenheimer raises Rhythm Pharmaceuticals stock price target to $110

Investing.com - Oppenheimer has increased its price target on Rhythm Pharmaceuticals (NASDAQ:RYTM) to $110.00 from $76.00 while maintaining an Outperform rating on the stock. The company, now valued at $5.66 billion, has seen its shares su... Full story